Skip to main content

Table 1 Baseline characteristics of the 14 patients with episodic CH who received GT in different cluster bouts

From: Preventive therapy with galcanezumab for two consecutive cluster bouts in patients with episodic cluster headache: an observational multicenter study

Age, years

38.1 ± 10.2

Male sex, n (%)

9 (64.3)

Onset age, years

26.4 ± 12.9

Duration of CH disease before 1st GT, years

3.1 (0.6, 8.9)

Duration between 1st GT and 2nd GT, months

10.0 (6.5, 17.5)

BMI, kg/m2

23.8 ± 2.5

Ever-smoker, n (%)

3 (21.4)

Current alcohol drinking, n (%)

5 (35.7)

Comorbid migraine, n (%)

5 (35.7)

PHQ-9 scorea

12.0 (5.0, 17.0)

GAD-7 scorea

10.0 (2.5, 15.0)

EQ-5D scoresa

0.9 (0.7, 0.9)

Passive suicidal ideaa

3 (21.4)

  1. Age, onset age and BMI are presented as mean ± standard deviation. The remaining data are presented as median (25th to 75th quartile) according to normality of variable
  2. CH Cluster headache, GT Galcanezumab therapy, BMI Body mass index, PHQ-9 Patient Health Questionnaire, GAD-7 Generalized Anxiety Disorder, EQ-5D Euro-Quality of Life-5 Dimension
  3. a Data about psychiatric comorbidities and suicidal idea were available among 11 patients. No patient attempted suicide